Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Parasitology ; 141(11): 1499-1509, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24927073

RESUMO

Specific roles of individual CDPKs vary, but in general they mediate essential biological functions necessary for parasite survival. A comparative analysis of the structure-activity relationships (SAR) of Neospora caninum, Eimeria tenella and Babesia bovis calcium-dependent protein kinases (CDPKs) together with those of Plasmodium falciparum, Cryptosporidium parvum and Toxoplasma gondii was performed by screening against 333 bumped kinase inhibitors (BKIs). Structural modelling and experimental data revealed that residues other than the gatekeeper influence compound-protein interactions resulting in distinct sensitivity profiles. We subsequently defined potential amino-acid structural influences within the ATP-binding cavity for each orthologue necessary for consideration in the development of broad-spectrum apicomplexan CDPK inhibitors. Although the BKI library was developed for specific inhibition of glycine gatekeeper CDPKs combined with low inhibition of threonine gatekeeper human SRC kinase, some library compounds exhibit activity against serine- or threonine-containing CDPKs. Divergent BKI sensitivity of CDPK homologues could be explained on the basis of differences in the size and orientation of the hydrophobic pocket and specific variation at other amino-acid positions within the ATP-binding cavity. In particular, BbCDPK4 and PfCDPK1 are sensitive to a larger fraction of compounds than EtCDPK1 despite the presence of a threonine gatekeeper in all three CDPKs.


Assuntos
Apicomplexa/enzimologia , Inibidores de Proteínas Quinases/farmacologia , Proteínas Quinases/genética , Infecções por Protozoários/parasitologia , Animais , Apicomplexa/genética , Babesia bovis/enzimologia , Babesia bovis/genética , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Eimeria tenella/enzimologia , Eimeria tenella/genética , Abastecimento de Alimentos , Humanos , Modelos Moleculares , Neospora/enzimologia , Neospora/genética , Inibidores de Proteínas Quinases/química , Inibidores de Proteínas Quinases/isolamento & purificação , Proteínas Quinases/metabolismo , Infecções por Protozoários/tratamento farmacológico , Proteínas de Protozoários/genética , Proteínas de Protozoários/metabolismo , Bibliotecas de Moléculas Pequenas , Relação Estrutura-Atividade , Medicina Veterinária
2.
ACS Med Chem Lett ; 5(1): 40-44, 2014 Jan 09.
Artigo em Inglês | MEDLINE | ID: mdl-24494061

RESUMO

5-Aminopyrazole-4-carboxamide was used as an alternative scaffold to substitute for the pyrazolopyrimidine of a known "bumped kinase inhibitor" to create selective inhibitors of calcium-dependent protein kinase-1 from both Toxoplasma gondii and Cryptosporidium parvum. Compounds with low nanomolar inhibitory potencies against the target enzymes were obtained. The most selective inhibitors also exhibited submicromolar activities in T. gondii cell proliferation assays and were shown to be non-toxic to mammalian cells.

3.
J Infect Dis ; 209(2): 275-84, 2014 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-24123773

RESUMO

Malaria parasites are transmitted by mosquitoes, and blocking parasite transmission is critical in reducing or eliminating malaria in endemic regions. Here, we report the pharmacological characterization of a new class of malaria transmission-blocking compounds that acts via the inhibition of Plasmodia CDPK4 enzyme. We demonstrate that these compounds achieved selectivity over mammalian kinases by capitalizing on a small serine gatekeeper residue in the active site of the Plasmodium CDPK4 enzyme. To directly confirm the mechanism of action of these compounds, we generated P. falciparum parasites that express a drug-resistant methionine gatekeeper (S147 M) CDPK4 mutant. Mutant parasites showed a shift in exflagellation EC50 relative to the wild-type strains in the presence of compound 1294, providing chemical-genetic evidence that CDPK4 is the target of the compound. Pharmacokinetic analyses suggest that coformulation of this transmission-blocking agent with asexual stage antimalarials such as artemisinin combination therapy (ACT) is a promising option for drug delivery that may reduce transmission of malaria including drug-resistant strains. Ongoing studies include refining the compounds to improve efficacy and toxicological properties for efficient blocking of malaria transmission.


Assuntos
Antimaláricos/metabolismo , Inibidores Enzimáticos/metabolismo , Plasmodium falciparum/efeitos dos fármacos , Proteínas Quinases/metabolismo , Proteínas de Protozoários/antagonistas & inibidores , Animais , Antimaláricos/isolamento & purificação , Antimaláricos/farmacocinética , Inibidores Enzimáticos/isolamento & purificação , Inibidores Enzimáticos/farmacocinética , Flagelos/efeitos dos fármacos , Flagelos/fisiologia , Camundongos , Plasmodium falciparum/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...